Grossberg, George, Meng, Xiangyi, Olin, Jason T.

Background: Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer’s disease (AD).; Methods: Post hoc analysis of a 24-week, prospective, international, randomized, double-blind, placebo- and active-controlled trial. Patients (n = 892) with probable AD received rivastigmine transdermal patches (9.5 mg/24 hours [10 cm(2)]), […]

Alva, Gustavo, Grossberg, George T., Schmitt, Frederick A., Meng, Xiangyi, Olin, Jason T.

Objective: In Alzheimer’s disease (AD), rivastigmine has demonstrated statistically significant efficacy versus placebo on cognition and activities of daily living (ADL). The aim of this retrospective analysis was to further evaluate the treatment effects of rivastigmine on individual ADL items.; Methods: This exploratory analysis focused on the Alzheimer’s Disease Cooperative Study Activities of Daily Living […]

Guo, Qihao, Zhou, Yan, Wang, Chao-Jih, Huang, Young-Ming, Lee, Yi-Ta, Su, Muh-Hwan, Lu, Jiahong

Aim: Efficacy and safety of Cistanche tubulosa glycoside capsules (CTG capsule, Memoregain(®)) for treating Alzheimer’s disease (AD) were studied.; Methods: A total of 18 patients with AD administered with Memoregain(®) for 48 weeks were assessed for drug efficacy by Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog), Mini-Mental State Examination (MMSE), Activities of Daily Living (ADLs), Blessed […]

Guo, Ming-Dong, Zhou, Wen-Quan, Wei, Yun

Objective:; To observe clinical curative effect of Shenxiong Bushen Capsule for the treatment of mild vascular dementia (VaD), and probe the partial mechanism.; Methods: With a block random, double-blinded and controled clinical research method adopted, seventy patients with VaD were randomly assigned to two groups in a ratio of 5:2, including 50 cases in the […]

Cummings, Jeffrey L., Ferris, Steven H., Farlow, Martin R., Olin, Jason T., Meng, Xiangyi

Background: The Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) scale is widely used in Alzheimer trials. It assesses cognition, activities of daily living (ADLs), behavior and global functioning. To advance the understanding of relationships between the ADCS-CGIC and scores from other commonly used tools, this analysis investigated the ability of each domain to […]

Silver, Jonathan M., Koumaras, Barbara, Meng, Xiangyi, Potkin, Steven G., Reyes, Patricio F., Harvey, Philip D., Katz, Douglas I., Gunay, Ibrahim, Arciniegas, David B.

Objective: To investigate the safety, tolerability and efficacy of rivastigmine capsules (3-12 mg/day) in a 26-week, multi-centre, open-label extension of a double-blind study.; Methods: Patients with traumatic brain injury (TBI) and persistent cognitive impairment who had received rivastigmine (3-6 mg/day) or placebo for 12 weeks could enter the extension study and receive rivastigmine (< or […]

Olin, Jason T., Bhatnagar, Vinod, Reyes, Patricio, Koumaras, Barbara, Meng, Xiangyi, Brannan, Stephen

Objective: Rivastigmine, a dual cholinesterase inhibitor (ChEI), is widely approved for the symptomatic treatment of both mild-to-moderate Alzheimer’s disease (AD) and Parkinson’s disease dementia. Orally administered ChEIs may be associated with gastrointestinal (GI) side effects and add-on therapy with memantine, an N-methyl-d-aspartate receptor antagonist, approved for moderate-to-severe AD, may ameliorate such side effects. This was […]

Sadowsky, C. H., Farlow, M. R., Meng, X., Olin, J. T.

Objectives: To compare the safety and tolerability of switching patients with mild-to-moderate Alzheimer’s disease from donepezil to either rivastigmine capsule or transdermal patch.; Methods: Three studies investigated the switch from donepezil to rivastigmine; study US13 was a 26-week, single-arm, immediate-switch study; US18 was a 26-week, sequential cohort study (both studies evaluated rivastigmine capsules 3-12 mg/day); […]